Intentional introduction of disease has been rare (3). Consequently, the incident identified by Thalassinou and her colleagues arouses readers’ interest and inspires speculation.

References

Address for correspondence: W. Seth Carus, National Defense University, Bldg 62, 300 5th Ave SW, Washington, DC 20319, USA; email: carus.wndcenter@gmail.com

**Bifidobacterium longum Subspecies infantis**

Bacteremia in 3 Extremely Preterm Infants Receiving Probiotics

Eirin Esaiassen, Pauline Cavanagh, Erik Hjerde, Gunnar S. Simonsen, Ragnhild Støen, Claus Klingenberg

Author affiliations: University Hospital of North Norway, Tromsø, Norway (E. Esaiassen, P. Cavanagh, G.S. Simonsen, C. Klingenberg); Arctic University of Norway, Tromsø (E. Esaiassen, E. Hjerde, G.S. Simonsen, C. Klingenberg); St. Olav’s Hospital, Trondheim, Norway (R. Støen); Norwegian University of Science and Technology, Trondheim (R. Støen)

DOI: http://dx.doi.org/10.3201/eid2209.160033

To the Editor: Metaanalysis of randomized trials that tested different probiotics showed a reduction of ≈50% in necrotizing enterocolitis and all-cause deaths in preterm infants (1). Use of probiotics is increasing worldwide (2,3), and cases of probiotic sepsis were not reported among >5,000 infants in an updated review (1).

In Norway, a consensus-based protocol recommending prophylactic probiotic supplementation for preterm infants at highest risk for necrotizing enterocolitis (gestational age <28 weeks, birthweight <1,000 g) was introduced in 2014. After considering the safety profile, we investigated use in preterm infants of a widely used combination of oral probiotics (Infloran; Laboratorio Farmacéutico Specialità Igienico Terapeutiche, Mede, Italy) that contained 10^9 Lactobacillus acidophilus (ATCC 4356) and 10^9 Bifidobacterium longum subspecies infantis (ATCC 15697).

*B. longum* is a microaerotolerant, anaerobic bacterium susceptible to many antimicrobial drugs (Table). This bacterium is a rare cause of neonatal infections; until 2015, only 2 *Bifidobacterium* bacteremia cases in premature newborns had been reported (4,5).

A total of 290 extremely preterm infants received oral probiotics during April 2014–August 2015 in Norway. Three patients were given a diagnosis of *B. longum* bacteremia: 2 patients in a neonatal unit in which 17 patients were given oral probiotics and 1 patient in a neonatal unit in which 31 patients were given oral probiotics (Table).

All 3 infants had respiratory distress syndrome and received mechanical ventilation after birth. Enteral feeding with human milk was begun on day 1. Oral probiotics (½ capsule, 1×/d) were given during the first week of life and increased to 1 capsule/day after 4–7 days.

We identified *B. longum* in blood cultures by using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonics, Billerica, MA, USA). Whole-genome sequencing (MiSeq, Illumina, San Diego, CA, USA) and comparative analysis of nucleotide-level variation by using variant cell format in SAMtools (http://samtools.sourceforge.net) showed that all 3 blood culture isolates and a *B. longum* strain cultured from an oral probiotic capsule were identical.

Patient 1 had sepsis and severe hypotension 8 days after birth. A blood culture was prepared, and the patient was given antimicrobial drugs and vasoactive support. Abdominal distention, gastric residuals, and feed intolerance developed the next day, but the patient was cardiorespiratory stable. On day 12, abdominal radiographs showed pneumoperitoneum. Surgery showed multiple ileal perforations and bowel necrosis. Histologic analysis showed classical features of necrotizing enterocolitis. The patient received an ileostoma and improved after treatment with antimicrobial drugs. Blood culture was positive for gram-positive rods, which were identified as *B. longum*. Subsequent clinical course was uneventful.

Patient 2 had apnea, bradycardia, and temperature instability 12 days after birth. A blood culture was prepared, and the patient was given antimicrobial drugs. Blood culture was positive for gram-positive rods, which were identified as *B. longum*. Use of oral probiotics was discontinued. The patient recovered rapidly, and subsequent clinical course was uneventful.

Patient 3 had sepsis and necrotizing enterocolitis 9 days after birth. Ultrasound showed free abdominal fluid. A blood culture was prepared, and the patient was given antimicrobial drugs. Surgery showed 2 separate bowel perforations, and
the patient received an ileostomy and colostoma. Histologic analysis did not show necrosis or inflammation. Enterococcus faecalis grew in the blood culture obtained on day 9. The patient had a complicated clinical course and received prolonged mechanical ventilation. However, the patient gradually tolerated full feeds. Use of oral probiotics was continued.

On day 46, the condition of patient 3 suddenly deteriorated; hypotension and metabolic acidosis developed, and the patient was again given antimicrobial drugs. A blood culture was positive for B. longum. Supplementation with oral probiotics was discontinued. The patient recovered from the infection, but secondary ileus developed. The patient had a complicated clinical course until discharge.

Recently, 5 other B. longum bacteremia cases among 5 preterm infants at 26–31 weeks gestation were reported (6,7). All 5 infants had received oral probiotics; 3 had severe gastrointestinal complications, similar to patient 1 in our report, and 2 patients were moderately compromised, similar to patient 2 (6,7).

We do not know whether Bifidobacterium organisms in blood culture for patient 1 were a consequence of intestinal necrosis and bacterial translocation or the cause of necrotizing enterocolitis. Patient 3 probably had a leaky gut that predisposed this patient to bacterial translocation. All 3 patients were extremely premature (23–24 weeks gestation) and had impaired immune systems, which predisposed them to infections with bacteria with low virulence. A recently published case of Bifidobacterium bacteremia in a 2-year old boy with leukemia highlights impaired immunity as a risk factor (8).

Only aerobic blood cultures are prepared for neonates. We detected Bifidobacterium bacteremia by using 2 automated blood culture systems and aerobic bottles. However, the sensitivity of these systems for detecting Bifidobacterium bacteremia is unknown. Thus, the incidence of Bifidobacterium bacteremia is theoretically underestimated. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry improves species detection and its use might be 1 reason for the apparently recent increase in probiotic-associated bacteremia.

We report that systemic infection with probiotic bacteremia might have a severe clinical course in extremely preterm infants. Clinical suspicion and appropriate blood culture conditions are essential for proper diagnosis and management.

References


Table. Characteristics of 3 extremely preterm infants with Bifidobacterium longum subspecies infantis bacteremia, 2015

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICU</td>
<td>A</td>
<td>B</td>
<td>A</td>
</tr>
<tr>
<td>Sex</td>
<td>M</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>Date of onset</td>
<td>Apr</td>
<td>Jul</td>
<td>Sep</td>
</tr>
<tr>
<td>Gestational age, wk</td>
<td>24</td>
<td>23</td>
<td>24</td>
</tr>
<tr>
<td>Birth weight, g</td>
<td>730</td>
<td>500</td>
<td>697</td>
</tr>
<tr>
<td>Mode of delivery</td>
<td>Vaginal</td>
<td>Vaginal</td>
<td>Caesarean section</td>
</tr>
<tr>
<td>Age at onset of sepsis, d</td>
<td>8</td>
<td>12</td>
<td>46</td>
</tr>
<tr>
<td>Maximum CRP level, mg/L, ≤48 h of symptom onset</td>
<td>147</td>
<td>25</td>
<td>242</td>
</tr>
<tr>
<td>Age at discharge, wk</td>
<td>40</td>
<td>41</td>
<td>43</td>
</tr>
<tr>
<td>Weight at discharge, kg</td>
<td>3.3</td>
<td>3.4</td>
<td>3.3</td>
</tr>
<tr>
<td>Bacterial culture medium and conditions</td>
<td>Bact/ALERT,† aerobic,</td>
<td>BACTEC Plus,† aerobic,</td>
<td>Bact/ALERT,† aerobic,</td>
</tr>
<tr>
<td></td>
<td>36°C</td>
<td>35°C</td>
<td>36°C</td>
</tr>
<tr>
<td>Bacterial growth in blood culture, d</td>
<td>2</td>
<td>3</td>
<td>2</td>
</tr>
</tbody>
</table>

*Patients were given ½ to 1 capsule/day of oral probiotics (Infloran; Laboratorio Farmaceutico Specialità Igienico Terapeutiche, Mede, Italy) that contained 10^9 Lactobacillus acidophilus (ATCC 4356) and 10^9 B. longum subspecies infantis (ATCC 15697). MICs (mg/L) for antimicrobial drugs tested were 0.016 for meropenem, 0.032 for ampicillin, 0.064 for piperacillin/tazobactam, 0.250 for cefotaxime, 0.250 for clindamycin, 0.250 for vancomycin, and 4.000 for ciprofloxacin. All bacterial strains were inherently resistant to aminoglycosides. ATCC, American Type Culture Collection (Manassas, VA, USA); CRP, C-reactive protein; NICU, neonatal intensive care unit.

Mohit Kumar

Author affiliation: Biotechnology and Bioinformatics, NIIT University, Neemrana, India

DOI: http://dx.doi.org/10.3201/eid2209.160044

To the Editor: Methicillin-resistant Staphylococcus aureus (MRSA) is a versatile pathogen capable of causing a wide variety of human diseases. Increased frequency of S. aureus infections imposes a high and increasing burden on healthcare resources. In many countries, MRSA infections in hospitals are common. Data from the National Nosocomial Infections Surveillance system suggest that, in the United States, incidence of nosocomial MRSA infections is steadily increasing and that these infections account for >60% of intensive care unit admissions (1,2). S. aureus has developed resistance to several antimicrobial drugs, including second- and third-line drugs. Only a few drugs, such as vancomycin (a glycopeptide), daptomycin (a lipopeptide), and linezolid (an oxazolidinone), have been approved for the treatment of serious infections caused by MRSA. Another drug, tigecycline (a glycylcycline), has shown good activity against MRSA strains in vitro (3). The epidemiology of MRSA is constantly changing, which results in variation in its drug-resistance patterns throughout regions and countries (4). Therefore, to support clinicians in preventing and treating infection, epidemiologic surveillance is essential. We report resistance patterns of S. aureus collected over 2 years (December 2013–November 2015) from blood samples of patients admitted to 1 hospital in Odisha, eastern India.

A total of 47 S. aureus isolates were collected; only 1 isolate per patient was included in the study. Susceptibility of the isolates was tested against antimicrobial agents according to the Clinical and Laboratory Standards Institute broth microdilution procedure and interpretation criteria (http://clsi.org/). MICs for the isolates were confirmed by using a Vitek 2 Compact automated system (bioMérieux, Marcy l’Étoile, France). S. aureus ATCC 25923 was used as a control strain. S. aureus identification was confirmed by using a Vitek 2 system, by hemolytic activity on blood agar, and by positive catalase activity test results. Clinical MRSA isolates were analyzed by using PCR with specific primers: mecA (5), cfr (6), and VanA (7).

Among the 47 S. aureus isolates, 28 (60%) were resistant to oxacillin (MICs 4–64 mg/L) and cefoxitin (MICs 8–64 mg/L). All MRSA isolates were able to grow in selective medium containing either aztreonam (75 mg/L) or colistin (10 mg/L). Screening of MRSA isolates showed that 2 isolates were highly resistant to vancomycin (MIC ≥100 mg/L) (Figure). Further screening showed that both vancomycin-resistant isolates were also resistant to linezolid (MIC ≥100 mg/L) (Figure). PCR amplification of both isolates indicated presence of all 3 genetic determinants: mecA (methicillin resistance), cfr (linzolid resistance), and VanA (vancomycin resistance). Among the 3 isolates that showed resistance to tigecycline (MIC ≥50 mg/L), 1 isolate was susceptible to vancomycin and linezolid (Figure). Unlike previously reported isolates, these 2 MRSA isolates showed resistant phenotypes to linezolid, tigecycline, and vancomycin.

MICs observed in this study were higher than those previously reported. Vancomycin-resistant S. aureus has been identified in many other countries. Most linezolid-resistant S. aureus has been isolated from patients in North America and Europe (8). The tigecycline-resistant S. aureus isolate (MIC >0.5 mg/L) reported from Brazil was also susceptible to linezolid, teicoplanin, and vancomycin (9).

This study indicates the emergence of multidrug-resistant S. aureus with co-resistance to methicillin, vancomycin, of the isolates was tested against antimicrobial agents according to the Clinical and Laboratory Standards Institute broth microdilution procedure and interpretation criteria (http://clsi.org/). MICs for the isolates were confirmed by using a Vitek 2 Compact automated system (bioMérieux, Marcy l’Étoile, France). S. aureus ATCC 25923 was used as a control strain. S. aureus identification was confirmed by using a Vitek 2 system, by hemolytic activity on blood agar, and by positive catalase activity test results. Clinical MRSA isolates were analyzed by using PCR with specific primers: mecA (5), cfr (6), and VanA (7).

Among the 47 S. aureus isolates, 28 (60%) were resistant to oxacillin (MICs 4–64 mg/L) and cefoxitin (MICs 8–64 mg/L). All MRSA isolates were able to grow in selective medium containing either aztreonam (75 mg/L) or colistin (10 mg/L). Screening of MRSA isolates showed that 2 isolates were highly resistant to vancomycin (MIC ≥100 mg/L) (Figure). Further screening showed that both vancomycin-resistant isolates were also resistant to linezolid (MIC ≥100 mg/L) (Figure). PCR amplification of both isolates indicated presence of all 3 genetic determinants: mecA (methicillin resistance), cfr (linzolid resistance), and VanA (vancomycin resistance). Among the 3 isolates that showed resistance to tigecycline (MIC ≥50 mg/L), 1 isolate was susceptible to vancomycin and linezolid (Figure). Unlike previously reported isolates, these 2 MRSA isolates showed resistant phenotypes to linezolid, tigecycline, and vancomycin.

MICs observed in this study were higher than those previously reported. Vancomycin-resistant S. aureus has been identified in many other countries. Most linezolid-resistant S. aureus has been isolated from patients in North America and Europe (8). The tigecycline-resistant S. aureus isolate (MIC >0.5 mg/L) reported from Brazil was also susceptible to linezolid, teicoplanin, and vancomycin (9).

This study indicates the emergence of multidrug-resistant S. aureus with co-resistance to methicillin, vancomycin,

---

**Figure.** Distribution of various resistance types of *Staphylococcus aureus* isolates collected in eastern India, 2013–2015. LRSA, linezolid-resistant *S. aureus*; MRSA, methicillin-resistant *S. aureus*; MSSA, methicillin-sensitive *S. aureus*; TRSA, tigecycline-resistant *S. aureus*; VRSA, vancomycin-resistant *S. aureus*.